Everything below concerns body composition. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-16. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
== Notes == ^α Three countries - Mauritius, Saint Lucia, and Saudi Arabia - have not had figures reported by the FAO since the 1990s but are still included in the data; all three continue to produce coffee at a small scale. They are counted here as producing nations but not included in the global totals. ^β Values for China are estimated by the ICO.
== History == Opicapone was authorised for medical use in the European Union in June 2016. In February 2017, its developer Bial sold exclusive marketing rights for the United States and Canada to Neurocrine Biosciences for an initial payment of US$30 million. Opicapone was authorised for medical use in the United States in April 2020. Opicapone was approved based on evidence from two clinical trials (Trial 1/ NCT01568073, and Trial 2/NCT01227655) of 522 participants with Parkinson's disease (PD) whose symptoms were not well controlled while receiving their regular PD treatment. Trial 1 was conducted at 104 sites in 19 European countries, and Trial 2 was conducted at 69 sites in Argentina, Australia, Belgium, Chile, Czech Republic, Estonia, India, Israel, South Korea, Russia, South Africa and UK. There were two 12-week trials conducted in Parkinson's disease (PD) participants with inadequate control of their Parkinson's symptom ("off" time) while receiving carbidopa/levodopa PD medications. Participants were randomly selected to receive either opicapone or a placebo capsule once a day. Neither the participants nor the health care providers knew which treatment was being given until the trial was completed. In all of the trials, the participants kept daily diaries of the number of hours of "off" time for the three days before the evaluation visit. The benefit was evaluated by measuring the change from baseline in total daily "off" time in opicapone- and placebo-receiving participants.
It is 2.7 million times more radioactive than the same molar amount of natural uranium (mostly uranium-238), due to its proportionally shorter half-life. A sample of radium metal maintains itself at a higher temperature than its surroundings because of the radiation it emits. Natural radium (which is mostly 226Ra) emits mostly alpha particles, but other steps in its decay chain (the uranium or radium series) emit alpha or beta particles, and almost all particle emissions are accompanied by gamma rays. Experimental nuclear physics studies have shown that nuclei of several radium isotopes, such as 222Ra, 224Ra and 226Ra, have reflection-asymmetric ("pear-like") shapes. In particular, this experimental information on radium-224 has been obtained at ISOLDE using a technique called Coulomb excitation.
=== Pharmacokinetics === A single 40-mg oral dose of relugolix has been found to result in peak levels of relugolix of 29 ng/mL (47 nmol/L) after 1.5 hours. Steady-state levels are reached within 7 days with 40 mg/day relugolix administration. There is an approximate 2-fold accumulation of relugolix by 2 weeks of continuous administration. Food diminishes the oral bioavailability of relugolix by about 50%. Relugolix is a substrate for P-glycoprotein, which may have a limiting effect on its absorption and distribution. The plasma protein binding of relugolix is approximately 68 to 71% over a concentration range of 0.05 to 5 μg/mL. Relugolix is not a substrate for CYP3A4. The elimination half-life of relugolix is 36 to 65 hours across a dosage range of 20 to 180 mg/day. There is moderate to high interindividual variability in systemic exposure to relugolix. Relugolix is excreted mainly in feces (83%) and to a small degree in urine (4%). Only about 6% of a dose of relugolix is excreted unchanged.
Peter Sprague, Pierre Lamond and the affectionately called Charlie Sporck worked hand-in-hand, with support of the board of directors to transform the company into a multinational and world-class semiconductor concern. Immediately after becoming CEO, Sporck started a historic price war among semiconductor companies, which then trimmed the number of competitors in the field. Among the casualties to exit the semiconductor business were General Electric and Westinghouse. Cost control, overhead reduction and a focus on profits implemented by Sporck was the key element to National surviving the price war and subsequently in 1981 becoming the first semiconductor company to reach the US$1 billion annual sales mark. However, the foundation that made National successful was its expertise in analog electronics, TTL (transistor–transistor logic) and MOSFET (metal–oxide–semiconductor field-effect transistor) integrated circuit technologies. As they had while employed in Fairchild, Sporck and Lamond directed National Semiconductor towards the growing industrial and commercial markets and began to rely less on military and aerospace contracts. Those decisions coupled with inflationary growth in use of computers provided the market for the expansion of National. Meanwhile, sources of funds associated with Sprague coupled with creative structuring of cash flow buffering due to Sporck and Lamond provided the financing required for that expansion. Lamond and Sporck had also managed to attract and extract substantial funds to finance the expansion.
Sources: en.wikipedia.org
Pyrite is usually found associated with other sulfides or oxides in quartz veins, sedimentary rock, and metamorphic rock, as well as in coal beds and as a replacement mineral in fossils, but has also been identified in the sclerites of scaly-foot gastropods. Despite being nicknamed "fool's gold", pyrite is sometimes found in association with small quantities of actual gold. A substantial proportion of this is "invisible gold" incorporated into the pyrite. It has been suggested that the presence of both gold and arsenic is a case of coupled substitution. However, as of 1997, the chemical state of the gold remained controversial.
== Nomenclature == A tRNA is commonly named by its intended amino acid (e.g. tRNA-Asn), by its anticodon sequence (e.g. tRNA(GUU)), or by both (e.g. tRNA-Asn(GUU) or tRNAAsnGUU). These two features describe the main function of the tRNA, but do not actually cover the whole diversity of tRNA variation; as a result, numerical suffixes are added to differentiate. tRNAs intended for the same amino acid are called "isotypes"; when isotypes also share the same anticodon they are called "isoacceptors"; and when isotypes have an identical mature sequence they are called "isodecoders".
=== Aftermath === An informal memorial was held for Staley on the night of April 20, 2002, at the Seattle Center, which was attended by at least 100 fans and friends, including Alice in Chains bandmates Cantrell, Starr, Inez and Kinney, and Soundgarden frontman Chris Cornell. Staley's body was cremated and a private memorial service was held for him on April 28, 2002 at Kiana Lodge in Poulsbo, Washington. During her appearance on Celebrity Rehab in 2010, Staley's mother said she has kept his ashes in a box. Staley's private memorial was attended by his family and friends, along with his Alice in Chains bandmates, the band's manager Susan Silver and her then-husband Chris Cornell, as well as other music personalities. Chris Cornell, joined by Heart's Ann and Nancy Wilson, sang a rendition of The Rolling Stones' "Wild Horses" at the funeral. They also performed The Lovemongers' song "Sand". Jerry Cantrell dedicated his solo album, Degradation Trip, released two months after Staley's death, to his memory. Cantrell also took in Staley's cat, Sadie, who he and the family took care of until Sadie's death in 2010, at the age of 18. Shortly after Staley's death, his parents Nancy McCallum and Phil Staley started receiving donations from fans all over the world. Nancy and Phil worked with Seattle's Therapeutic Health Services clinic to create the Layne Staley Memorial Fund to help other heroin addicts and their families in the Seattle music community. Alice in Chains remained inactive following Staley's death.
However, the subsequent era under Leonid Brezhnev, sometimes referred to as the Era of Stagnation, was marked by economic decline, political corruption, and a rigid gerontocracy. Despite efforts to maintain the Soviet Union's superpower status, the economy struggled due to its centralized nature, technological backwardness, and inefficiencies. The vast military expenditures, and the Eastern Bloc halting embezzlement of its resources; further strained the Soviet economy. In the 1980s, Mikhail Gorbachev's policies of glasnost (openness) and perestroika (restructuring) aimed to revitalize the Soviet system but instead accelerated its unraveling. Nationalist movements gained momentum across the Soviet republics and the control of the Communist Party weakened. The failed coup attempt in August 1991 against Gorbachev by hardline communists hastened the end of the Soviet Union, which formally dissolved on 26 December 1991, ending nearly seven decades of Soviet rule.
As with other ratites, emus have a relatively low basal metabolic rate compared to other types of birds. At −5 °C (23 °F), the metabolic rate of an emu sitting down is about 60% of that when standing, partly because the lack of feathers under the stomach leads to a higher rate of heat loss when standing from the exposed underbelly.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.